M Pharmaceutical to Open Bulgaria Unit for Trimeo Registration

M Pharmaceutical Inc. (CSE:MQ) announced today plans to open a subsidiary company, M Pharma Bulgaria Ltd., to achieve registration of the companies Trimeo device in the European Union.
As quoted in the press release:

M Pharmaceutical Inc.’s board of directors has made a decision to open a fully owned subsidiary company, M Pharma Bulgaria Ltd., with a clear mandate to achieve registration of the company’s temporary controllable pseudobezoar technology, Trimeo, as a medical device in the European Union and to obtain a CE Mark for it. M Pharma Bulgaria will collaborate with Medica AD (Bulgaria), a leading producer of CE-certified medical materials in eastern Europe, and with local vendors to achieve these objectives.

President and CEO of M Pharmaceutical Inc. Dr. Martin Mintchev stated:

Opening a subsidiary in Bulgaria, an European Union member state, demonstrates our commitment to quickly move towards registering Trimeo as a prescription-based medical device for the treatment of obesity in the European Union. “We are confident that obtaining CE Mark for Trimeo and starting sales in Europe will strengthen our regulatory position with the U.S. Food and Drug Administration and Health Canada on our quest for subsequently entering the North American market.

Click here for the M Pharmaceutical Inc. (CSE:MQ) press release.
Click here for the M Pharmaceutical Inc. (CSE:MQ) profile.